

Special Issue

Novel Technology and Vaccines Development for COVID-19

Message from the Guest Editors

The continuous mutation of SARS-CoV-2 is challenging the efficacy of applied vaccines. Therefore, it is urgently necessary to develop convenient, self-usable diagnostics or prevention tools based on mucosal technology in order to reduce side effects and increase accessibility. The fight against COVID-19 continues; therefore, it is crucial that we make progress regarding the development, improvement and effectiveness of COVID-19 vaccines. Research areas may include (but not limited to) the following:

- The progress in the designs, evaluations, and clinical trials in novel vaccines against SARS-CoV-2;
- The development of universal vaccines to overcome SARS-CoV-2 variation;
- The principles of escape neutralization caused by variation;
- The models applied to evaluate vaccines in vitro or in vivo;
- The novel tools for COVID-19 prevention and control to target immunogen sites;
- The identification of universal or new immunogen targets of SARS-CoV-2.

We look forward to receiving your contributions.

Guest Editors

Dr. Chang Li

Dr. Penghua Wang

Prof. Dr. Bin Zhou

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/117271

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).